BioMérieux has a total of 6078 patents globally, out of which 1061 have been granted. Of these 1839 patents, more than 44% patents are active. The United States of America is where BioMérieux has filed the maximum number of patents, followed by Europe and Japan. Parallelly, The United States of America seems to be the main focused R&D center and also France is the origin country of BioMérieux.
BioMérieux was founded in the year 1963. The Company provides diagnostic solutions and also offers vaccines and biological products for diagnosis of infectious diseases such as hepatitis, tuberculosis, respiratory infections, and cancer. BioMérieux serves patients worldwide.
Do read about some of the most popular patents of BioMérieux which have been covered by us in this article and also you can find BioMérieux patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over BioMérieux patent portfolio.
How many patents does the Founder and CEO of BioMérieux have?
The Founder Alain Mérieux has 0 patents and the CEO Alexandre Merieux have 0 patents.
How many patents does BioMérieux have?
BioMérieux has a total of 6078 patents globally. These patents belong to 1406 unique patent families. Out of 6078 patents, 2696 patents are active.
How Many Patents did BioMérieux File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
Year of Patents Filing or Grant | bioMérieux Applications Filed | bioMérieux Patents Granted |
2023 | – | 36 |
2022 | 21 | 166 |
2021 | 83 | 187 |
2020 | 131 | 201 |
2019 | 110 | 224 |
2018 | 192 | 283 |
2017 | 202 | 236 |
2016 | 279 | 262 |
2015 | 305 | 239 |
2014 | 365 | 227 |
2013 | 404 | 169 |
2012 | 407 | 125 |
2011 | 337 | 117 |
How many BioMérieux patents are Alive/Dead?
Worldwide Patents
How Many Patents did BioMérieux File in Different Countries?
Countries in which BioMérieux Filed Patents
Country | Patents |
United States Of America | 958 |
Europe | 891 |
Japan | 512 |
Germany | 494 |
France | 437 |
China | 436 |
Australia | 319 |
Spain | 297 |
Austria | 162 |
Canada | 162 |
India | 139 |
Brazil | 95 |
Hong Kong (S.A.R.) | 88 |
Korea (South) | 65 |
New Zealand | 64 |
Mexico | 49 |
Italy | 28 |
Denmark | 27 |
Portugal | 25 |
Poland | 22 |
Israel | 22 |
Singapore | 20 |
Russia | 19 |
Eurasia | 16 |
United Kingdom | 15 |
South Africa | 9 |
Slovenia | 8 |
Hungary | 4 |
Taiwan | 3 |
Cyprus | 3 |
Croatia | 3 |
Norway | 3 |
Africa | 3 |
Malta | 2 |
Belgium | 2 |
Turkey | 2 |
Albania | 2 |
Indonesia | 2 |
Ireland | 2 |
Chile | 2 |
San Marino | 2 |
Colombia | 1 |
Switzerland | 1 |
Serbia | 1 |
Sweden | 1 |
Where are Research Centers of BioMérieux Patents Located?
10 Best BioMérieux Patents
US7387887B2 is the most popular patent in the BioMérieux portfolio. It has received 205 citations so far from companies like Life Technologies Corporation, BD and Helix, Inc.
Below is the list of 10 most cited patents of BioMérieux:
Publication Number | Citation Count |
US7387887B2 | 205 |
US20060046246A1 | 153 |
US6489114B2 | 138 |
US6635427B2 | 137 |
US6686195B1 | 135 |
US6340571B1 | 133 |
US8394608B2 | 130 |
US6342396B1 | 111 |
US20070240986A1 | 111 |
US20100129857A1 | 97 |
How many inventions of other companies were rejected due to BioMérieux patents?
The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to BioMérieux invention. They couldn’t because BioMérieux had protected those before them.
Examiners at the USPTO referred 813 BioMérieux patents in 205 rejections (35 USC § 102 or 35 USC § 103 types).
The top citing companies in the BioMérieux patent portfolio are Biofire Diagnostics, Capital Royalty Partners and Canon.
List of the Companies whose Patents were rejected citing BioMérieux –
Company | Number of Patent Applications that faced Rejection Citing bioMérieux Patents | Number of Rejections (102 & 103) |
Biofire Diagnostics | 14 | 24 |
Capital Royalty Partners Ii Lp | 12 | 20 |
Canon | 11 | 22 |
Becton Dickinson | 6 | 13 |
Arkray | 6 | 10 |
Parallel Investment Opportunities Partners Ii Lp | 6 | 10 |
Roche Molecular Systems Inc | 5 | 10 |
Siemens Healthcare Diagnostics Ltd | 5 | 11 |
IBM | 5 | 7 |
Philips | 4 | 6 |
Count of 102 and 103 Type Rejections based on BioMérieux Patents
Top BioMérieux Patents used in Rejecting Most Patent Applications
Patent Number | Count of Rejected Applications |
US8394608B2 | 12 |
US20060046246A1 | 10 |
US8841118B2 | 9 |
US8895295B2 | 9 |
US7387887B2 | 9 |
US6635427B2 | 8 |
US20090178935A1 | 7 |
US7630837B2 | 6 |
US20040197833A1 | 6 |
US20020052419A1 | 5 |
US11150250B2 | 5 |
US9029093B2 | 5 |
US9733261B2 | 4 |
US7456281B2 | 4 |
US7159618B2 | 4 |
What Percentage of BioMérieux US Patent Applications were Granted?
BioMérieux (Excluding its subsidiaries) has filed 659 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 495 have been granted leading to a grant rate of 79.97%.
Below are the key stats of BioMérieux patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for BioMérieux?
Law Firm | Total Applications | Success Rate |
Oliff Plc | 198 | 71.35% |
Biomerieux Inc | 128 | 88.43% |
Myers Bigel | 44 | 85.00% |
Mcdonnell Boehnen Hulbert & Berghoff | 34 | 84.38% |
Alston & Bird | 29 | 100.00% |
James C Lydon | 16 | 56.25% |
Nicolas E Seckel | 14 | 75.00% |
Oblon Mcclelland Maier & Neustadt | 13 | 92.31% |
Parker Highlander Pllc | 13 | 69.23% |
Arlington Ladas & Parry | 12 | 83.33% |